Prevalence and duration of anti-SARS-CoV-2 antibodies in healthcare workers

Caroline Klint Johannesen; Gry St Martin; Maria Elisabeth Lendorf; Peter Gerred; Alexander Fyfe; Robert S Paton; Craig Thompson; Stig Molsted; Caroline Elisabeth Kann; Claus Antonio Jensen; Cecilie Bo Hansen; Ellen Løkkegaard; Thomas Broe Christensen; Peter Simons; Thea K. Fischer

Prevalence and duration of anti-SARS-CoV-2 antibodies in healthcare workers

Caroline Klint Johannesen
, Gry St Martin
, Maria Elisabeth Lendorf
, Peter Gerred
, Alexander Fyfe
, Robert S Paton
, Craig Thompson
, Stig Molsted
, Caroline Elisabeth Kann
, Claus Antonio Jensen
, Cecilie Bo Hansen
, Ellen Løkkegaard
, Thomas Broe Christensen
, Peter Simons
, Thea K. Fischer

Centre for Health Research

Research output: Contribution to journal › Article › Research › peer-review

Abstract

INTRODUCTION: Knowledge of the seroprevalence and duration of antibodies against SARS-CoV-2 was needed in the early phases of the COVID-19 pandemic and is still necessary for policy makers and healthcare professionals. This information allows us to better understand the risk of reinfection in previously infected individuals.

METHODS: We investigated the prevalence and duration of detectable antibodies against SARS-CoV-2 in sequentially collected samples from 379 healthcare professionals.

RESULTS: SARS-CoV-2 seroprevalence at inclusion was 5.3% (95% confidence interval (CI): 3.3-8.0%) and 25% of seropositive participants reverted during follow-up. At the end of follow-up, the calculated probability of having detectable antibodies among former seropositive participants was 72.2% (95% CI: 54.2-96.2%).

CONCLUSION: Antibodies against SARS-CoV-2 were detectable in a subset of infected individuals for a minimum of 39 weeks.

FUNDING: The assays performed at Rigshospitalet were developed with financial support from the Carlsberg Foundation (CF20-0045) and the Novo Nordisk Foundation (NFF205A0063505 and NNF20SA0064201).

TRIAL REGISTRATION: The study was registered with the Danish National Committee on Health Research Ethics (H-20022312).

Original language	English
Article number	A11210843
Pages (from-to)	1-9
Number of pages	9
Journal	Danish Medical Journal
Volume	69
Issue number	5
Publication status	Published - 7 Apr 2022

Keywords

Antibodies, Viral
COVID-19/epidemiology
Health Personnel
Humans
Pandemics
Prevalence
SARS-CoV-2
Seroepidemiologic Studies

Access to Document

https://ugeskriftet.dk/dmj/prevalence-and-duration-anti-sars-cov-2-antibodies-healthcare-workers

Cite this

Johannesen, C. K., St Martin, G., Lendorf, M. E., Gerred, P., Fyfe, A., Paton, R. S., Thompson, C., Molsted, S., Kann, C. E., Jensen, C. A., Hansen, C. B., Løkkegaard, E., Christensen, T. B., Simons, P., & Fischer, T. K. (2022). Prevalence and duration of anti-SARS-CoV-2 antibodies in healthcare workers. Danish Medical Journal, 69(5), 1-9. Article A11210843. https://ugeskriftet.dk/dmj/prevalence-and-duration-anti-sars-cov-2-antibodies-healthcare-workers

@article{4aa8f9d189a0403eab2407397eef358c,

title = "Prevalence and duration of anti-SARS-CoV-2 antibodies in healthcare workers",

abstract = "INTRODUCTION: Knowledge of the seroprevalence and duration of antibodies against SARS-CoV-2 was needed in the early phases of the COVID-19 pandemic and is still necessary for policy makers and healthcare professionals. This information allows us to better understand the risk of reinfection in previously infected individuals.METHODS: We investigated the prevalence and duration of detectable antibodies against SARS-CoV-2 in sequentially collected samples from 379 healthcare professionals.RESULTS: SARS-CoV-2 seroprevalence at inclusion was 5.3\% (95\% confidence interval (CI): 3.3-8.0\%) and 25\% of seropositive participants reverted during follow-up. At the end of follow-up, the calculated probability of having detectable antibodies among former seropositive participants was 72.2\% (95\% CI: 54.2-96.2\%).CONCLUSION: Antibodies against SARS-CoV-2 were detectable in a subset of infected individuals for a minimum of 39 weeks.FUNDING: The assays performed at Rigshospitalet were developed with financial support from the Carlsberg Foundation (CF20-0045) and the Novo Nordisk Foundation (NFF205A0063505 and NNF20SA0064201).TRIAL REGISTRATION: The study was registered with the Danish National Committee on Health Research Ethics (H-20022312).",

keywords = "Antibodies, Viral, COVID-19/epidemiology, Health Personnel, Humans, Pandemics, Prevalence, SARS-CoV-2, Seroepidemiologic Studies",

author = "Johannesen, \{Caroline Klint\} and \{St Martin\}, Gry and Lendorf, \{Maria Elisabeth\} and Peter Gerred and Alexander Fyfe and Paton, \{Robert S\} and Craig Thompson and Stig Molsted and Kann, \{Caroline Elisabeth\} and Jensen, \{Claus Antonio\} and Hansen, \{Cecilie Bo\} and Ellen L{\o}kkegaard and Christensen, \{Thomas Broe\} and Peter Simons and Fischer, \{Thea K.\}",

note = "Articles published in the DMJ are “open access”. This means that the articles are distributed under the terms of the Creative Commons Attribution Non-commercial License, which permits any non-commercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.",

year = "2022",

month = apr,

day = "7",

language = "English",

volume = "69",

pages = "1--9",

journal = "Danish Medical Journal",

issn = "2245-1919",

publisher = "Almindelige Danske Laegeforening",

number = "5",

}

Johannesen, CK, St Martin, G, Lendorf, ME, Gerred, P, Fyfe, A, Paton, RS, Thompson, C, Molsted, S, Kann, CE, Jensen, CA, Hansen, CB, Løkkegaard, E, Christensen, TB, Simons, P & Fischer, TK 2022, 'Prevalence and duration of anti-SARS-CoV-2 antibodies in healthcare workers', Danish Medical Journal, vol. 69, no. 5, A11210843, pp. 1-9. <https://ugeskriftet.dk/dmj/prevalence-and-duration-anti-sars-cov-2-antibodies-healthcare-workers>

TY - JOUR

T1 - Prevalence and duration of anti-SARS-CoV-2 antibodies in healthcare workers

AU - Johannesen, Caroline Klint

AU - St Martin, Gry

AU - Lendorf, Maria Elisabeth

AU - Gerred, Peter

AU - Fyfe, Alexander

AU - Paton, Robert S

AU - Thompson, Craig

AU - Molsted, Stig

AU - Kann, Caroline Elisabeth

AU - Jensen, Claus Antonio

AU - Hansen, Cecilie Bo

AU - Løkkegaard, Ellen

AU - Christensen, Thomas Broe

AU - Simons, Peter

AU - Fischer, Thea K.

N1 - Articles published in the DMJ are “open access”. This means that the articles are distributed under the terms of the Creative Commons Attribution Non-commercial License, which permits any non-commercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.

PY - 2022/4/7

Y1 - 2022/4/7

N2 - INTRODUCTION: Knowledge of the seroprevalence and duration of antibodies against SARS-CoV-2 was needed in the early phases of the COVID-19 pandemic and is still necessary for policy makers and healthcare professionals. This information allows us to better understand the risk of reinfection in previously infected individuals.METHODS: We investigated the prevalence and duration of detectable antibodies against SARS-CoV-2 in sequentially collected samples from 379 healthcare professionals.RESULTS: SARS-CoV-2 seroprevalence at inclusion was 5.3% (95% confidence interval (CI): 3.3-8.0%) and 25% of seropositive participants reverted during follow-up. At the end of follow-up, the calculated probability of having detectable antibodies among former seropositive participants was 72.2% (95% CI: 54.2-96.2%).CONCLUSION: Antibodies against SARS-CoV-2 were detectable in a subset of infected individuals for a minimum of 39 weeks.FUNDING: The assays performed at Rigshospitalet were developed with financial support from the Carlsberg Foundation (CF20-0045) and the Novo Nordisk Foundation (NFF205A0063505 and NNF20SA0064201).TRIAL REGISTRATION: The study was registered with the Danish National Committee on Health Research Ethics (H-20022312).

AB - INTRODUCTION: Knowledge of the seroprevalence and duration of antibodies against SARS-CoV-2 was needed in the early phases of the COVID-19 pandemic and is still necessary for policy makers and healthcare professionals. This information allows us to better understand the risk of reinfection in previously infected individuals.METHODS: We investigated the prevalence and duration of detectable antibodies against SARS-CoV-2 in sequentially collected samples from 379 healthcare professionals.RESULTS: SARS-CoV-2 seroprevalence at inclusion was 5.3% (95% confidence interval (CI): 3.3-8.0%) and 25% of seropositive participants reverted during follow-up. At the end of follow-up, the calculated probability of having detectable antibodies among former seropositive participants was 72.2% (95% CI: 54.2-96.2%).CONCLUSION: Antibodies against SARS-CoV-2 were detectable in a subset of infected individuals for a minimum of 39 weeks.FUNDING: The assays performed at Rigshospitalet were developed with financial support from the Carlsberg Foundation (CF20-0045) and the Novo Nordisk Foundation (NFF205A0063505 and NNF20SA0064201).TRIAL REGISTRATION: The study was registered with the Danish National Committee on Health Research Ethics (H-20022312).

KW - Antibodies, Viral

KW - COVID-19/epidemiology

KW - Health Personnel

KW - Humans

KW - Pandemics

KW - Prevalence

KW - SARS-CoV-2

KW - Seroepidemiologic Studies

M3 - Article

C2 - 35485785

SN - 2245-1919

VL - 69

SP - 1

EP - 9

JO - Danish Medical Journal

JF - Danish Medical Journal

IS - 5

M1 - A11210843

ER -

Prevalence and duration of anti-SARS-CoV-2 antibodies in healthcare workers

Abstract

Keywords

Access to Document

Fingerprint

Cite this